| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Vicky L Kett | Q57636504 |
| Helmy Yusuf | Q85215221 | ||
| P2093 | author name string | Vicky Kett | |
| Helmy Yusuf | |||
| P2860 | cites work | Novel vaccine development strategies for inducing mucosal immunity | Q24607533 |
| Maintenance of Immune Homeostasis through ILC/T Cell Interactions | Q26796071 | ||
| Cationic liposome-hyaluronic acid hybrid nanoparticles for intranasal vaccination with subunit antigens | Q27310007 | ||
| Needle-free vaccine delivery | Q28303773 | ||
| Stable dry powder formulation for nasal delivery of anthrax vaccine | Q28386405 | ||
| Cross-talk between activated human NK cells and CD4+ T cells via OX40-OX40 ligand interactions | Q28609709 | ||
| Virus-like particle vaccine containing hemagglutinin confers protection against 2009 H1N1 pandemic influenza | Q28741801 | ||
| FOXP3+ regulatory T cells in the human immune system | Q29307487 | ||
| Induction of Th-1 and Th-2 responses by respiratory syncytial virus attachment glycoprotein is epitope and major histocompatibility complex independent. | Q30304128 | ||
| Intranasal immunization with liposome-encapsulated plasmid DNA encoding influenza virus hemagglutinin elicits mucosal, cellular and humoral immune responses. | Q30349731 | ||
| A pandemic influenza vaccine in India: from strain to sale within 12 months | Q30403994 | ||
| Cold-adapted pandemic 2009 H1N1 influenza virus live vaccine elicits cross-reactive immune responses against seasonal and H5 influenza A viruses | Q30414515 | ||
| An influenza simulation model for immunization studies | Q30421014 | ||
| A post-marketing surveillance study of a human live-virus pandemic influenza A (H1N1) vaccine (Nasovac (®) ) in India | Q30427619 | ||
| Nasal drug delivery devices: characteristics and performance in a clinical perspective-a review | Q30459229 | ||
| Impact of chitosan coating of anionic liposomes on clearance rate, mucosal and systemic immune responses following nasal administration in rabbits | Q30872496 | ||
| Phase 1 evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labile toxin in adult volunteers | Q33650384 | ||
| Selective IgA deficiency | Q33651307 | ||
| Oral vaccine delivery | Q33852928 | ||
| A novel intranasal breath-powered delivery system for sumatriptan: a review of technology and clinical application of the investigational product AVP-825 in the treatment of migraine | Q38539637 | ||
| Protective role of Th17 cells in pulmonary infection | Q38734006 | ||
| Immune response elicited by an intranasally delivered HBsAg low-dose adsorbed to poly-ε-caprolactone based nanoparticles. | Q38786375 | ||
| Development of polymeric-cationic peptide composite nanoparticles, a nanoparticle-in-nanoparticle system for controlled gene delivery. | Q38813247 | ||
| Molecular investigations into vaginal immunization with HIV gp41 antigenic construct H4A in a quick release solid dosage form. | Q39648706 | ||
| Epithelial cells as sensors for microbial infection | Q39786521 | ||
| Cellular gene transfer mediated by influenza virosomes with encapsulated plasmid DNA. | Q40159983 | ||
| Development and in vitro validation of a targeted delivery vehicle for DNA vaccines. | Q40302011 | ||
| Effectiveness of virosomal subunit influenza vaccine in preventing influenza-related illnesses and its social and economic consequences in children aged 3-14 years: a prospective cohort study. | Q40474518 | ||
| Intranasal Administration of Novel Chitosan Nanoparticle/DNA Complexes Induces Antibody Response to Hepatitis B Surface Antigen in Mice. | Q41063700 | ||
| Vaccines for mucosal immunity to combat emerging infectious diseases | Q33886205 | ||
| Induction of CD4(+) T cell-dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine. | Q33943869 | ||
| Collaboration of epithelial cells with organized mucosal lymphoid tissues. | Q33955758 | ||
| The functional interactions of commensal bacteria with intestinal secretory IgA. | Q34007246 | ||
| Chitosan: a promising safe and immune-enhancing adjuvant for intranasal vaccines | Q34033764 | ||
| PLGA, PLGA-TMC and TMC-TPP nanoparticles differentially modulate the outcome of nasal vaccination by inducing tolerance or enhancing humoral immunity | Q34071603 | ||
| Plasmodium vivax ookinete surface protein Pvs25 linked to cholera toxin B subunit induces potent transmission-blocking immunity by intranasal as well as subcutaneous immunization | Q34119427 | ||
| Intestinal IgA synthesis: regulation of front-line body defences | Q34168492 | ||
| Robust IgA and IgG-producing antibody forming cells in the diffuse-NALT and lungs of Sendai virus-vaccinated cotton rats associate with rapid protection against human parainfluenza virus-type 1 | Q34175747 | ||
| Nature and function of gastrointestinal antigen-presenting cells | Q34215953 | ||
| Educating CD4 T cells with vaccine adjuvants: lessons from lipopolysaccharide | Q34258820 | ||
| Innate immune responses of epithelial cells following infection with bacterial pathogens | Q34332645 | ||
| High-level primary CD8(+) T-cell response to human immunodeficiency virus type 1 gag and env generated by vaccination with recombinant vesicular stomatitis viruses | Q34333167 | ||
| NALT- versus Peyer's-patch-mediated mucosal immunity | Q34345343 | ||
| Mucosal immunity and vaccines | Q34409172 | ||
| An intranasally delivered Toll-like receptor 7 agonist elicits robust systemic and mucosal responses to Norwalk virus-like particles | Q34431983 | ||
| Application of galactose-modified liposomes as a potent antigen presenting cell targeted carrier for intranasal immunization. | Q34480262 | ||
| The IgA system: a comparison of structure and function in different species. | Q34513215 | ||
| Partial reconstitution of the CD4+-T-cell compartment in CD4 gene knockout mice restores responses to tuberculosis DNA vaccines | Q34601896 | ||
| Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation. | Q34623431 | ||
| Induction of mucosal immune responses and protection of cattle against direct-contact challenge by intranasal delivery with foot-and-mouth disease virus antigen mediated by nanoparticles | Q34661842 | ||
| Structure and function of the polymeric mucins in airways mucus. | Q34686458 | ||
| The immune geography of IgA induction and function | Q34903056 | ||
| Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany | Q35618994 | ||
| Seasonal influenza vaccination for children in Thailand: a cost-effectiveness analysis | Q35642206 | ||
| Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial | Q35679839 | ||
| NKp46+ Innate Lymphoid Cells Dampen Vaginal CD8 T Cell Responses following Local Immunization with a Cholera Toxin-Based Vaccine. | Q35858827 | ||
| Mucosal adjuvants | Q36055990 | ||
| Nanoparticles as carriers for nasal vaccine delivery. | Q36124952 | ||
| Protection from the acquisition of Staphylococcus aureus nasal carriage by cross-reactive antibody to a pneumococcal dehydrogenase | Q36187255 | ||
| Bacterial exposure induces and activates matrilysin in mucosal epithelial cells | Q36326278 | ||
| Innate sensors of microbial infection | Q36354695 | ||
| AVP-825 breath-powered intranasal delivery system containing 22 mg sumatriptan powder vs 100 mg oral sumatriptan in the acute treatment of migraines (The COMPASS study): a comparative randomized clinical trial across multiple attacks | Q36380205 | ||
| Mucosal vaccines: the promise and the challenge | Q36402244 | ||
| Mucosal IgA responses in healthy adult volunteers following intranasal spray delivery of a live attenuated measles vaccine. | Q41941037 | ||
| Inactivated influenza vaccine adjuvanted with bacterium-like particles induce systemic and mucosal influenza A virus specific T-cell and B-cell responses after nasal administration in a TLR2 dependent fashion. | Q42225520 | ||
| PLGA nanoparticles enhance the expression of retinaldehyde dehydrogenase enzymes in dendritic cells and induce FoxP3(+) T-cells in vitro | Q42270696 | ||
| Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines. | Q43012213 | ||
| Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod, Russia. | Q43208959 | ||
| Synthesis, characterization and evaluation of novel triblock copolymer based nanoparticles for vaccine delivery against hepatitis B. | Q43450878 | ||
| Upper and lower airway nitric oxide levels in primary ciliary dyskinesia, cystic fibrosis and asthma | Q44067662 | ||
| Pre-clinical and clinical investigation of the safety of a novel adjuvant for intranasal immunization | Q44191512 | ||
| Search for Herpesviruses in cerebrospinal fluid of facial palsy patients by PCR. | Q44389878 | ||
| Type 2 innate lymphoid cells drive CD4+ Th2 cell responses | Q44613459 | ||
| Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model | Q44642105 | ||
| TLR9 agonist CpG enhances protective nasal HSP60 peptide vaccine efficacy in experimental autoimmune arthritis | Q44663546 | ||
| Intranasal vaccination with an adjuvanted Norwalk virus-like particle vaccine elicits antigen-specific B memory responses in human adult volunteers. | Q45356767 | ||
| Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant | Q45378308 | ||
| Intranasal immunization with mumps virus DNA vaccine delivered by influenza virosomes elicits mucosal and systemic immunity. | Q45739896 | ||
| Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines | Q45744584 | ||
| MHC class II presentation of endogenously expressed antigens by transfected dendritic cells | Q45876566 | ||
| Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1. | Q46325181 | ||
| In vivo evaluation of nicotine lyophilised nasal insert in sheep | Q46720021 | ||
| The effect of polymer coatings on physicochemical properties of spray-dried liposomes for nasal delivery of BSA. | Q47957588 | ||
| Strong local and systemic protective immunity induced in the ferret model by an intranasal virosome-formulated influenza subunit vaccine. | Q50750265 | ||
| TLR2 stimulation drives human naive and effector regulatory T cells into a Th17-like phenotype with reduced suppressive function. | Q50999206 | ||
| Intranasal immunization promotes th17 immune responses. | Q53061770 | ||
| Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen. | Q53311940 | ||
| Oral or nasal antigen induces regulatory T cells that suppress arthritis and proliferation of arthritogenic T cells in joint draining lymph nodes. | Q53467817 | ||
| Mucosal antibody response induced with a nasal virosome-based influenza vaccine. | Q53854894 | ||
| The diacylated lipopeptide FSL-1 induces TLR2-mediated Th2 responses. | Q54455967 | ||
| Intranasal immunisation of mice with liposomes containing recombinant meningococcal OpaB and OpaJ proteins. | Q54499826 | ||
| Epidermal immunization by a needle-free powder delivery technology: Immunogenicity of influenza vaccine and protection in mice | Q56772848 | ||
| IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge | Q58518610 | ||
| A novel bioadhesive intranasal delivery system for inactivated influenza vaccines | Q73447989 | ||
| Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine containing Escherichia coli heat-labile toxin as a mucosal adjuvant | Q73556624 | ||
| Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland | Q76383446 | ||
| The rheology of nasal mucus: a review | Q77504214 | ||
| Surface modified liposomes for nasal delivery of DNA vaccine | Q81038743 | ||
| Re-formulating drugs and vaccines for intranasal delivery: maximum benefits for minimum risks? | Q82444243 | ||
| Intranasal immunization with an apolipoprotein B-100 fusion protein induces antigen-specific regulatory T cells and reduces atherosclerosis | Q82956532 | ||
| Establishment of nasal tolerance to heat shock protein-60 alleviates atherosclerosis by inducing TGF-β-dependent regulatory T cells | Q83335860 | ||
| Oral tolerance | Q83849376 | ||
| Nasal vaccination with P6 outer membrane protein and alpha-galactosylceramide induces nontypeable Haemophilus influenzae-specific protective immunity associated with NKT cell activation and dendritic cell expansion in nasopharynx | Q84241823 | ||
| Nanogel vaccines targeting dendritic cells: contributions of the surface decoration and vaccine cargo on cell targeting and activation | Q85635065 | ||
| Development and characterization of surface modified PLGA nanoparticles for nasal vaccine delivery: effect of mucoadhesive coating on antigen uptake and immune adjuvant activity | Q87053134 | ||
| Applications of influenza virosomes as a delivery system. | Q36609105 | ||
| Nanoparticulate systems for nasal delivery of drugs: a real improvement over simple systems? | Q36659060 | ||
| Debugging how bacteria manipulate the immune response. | Q36739044 | ||
| The perfect mix: recent progress in adjuvant research | Q36844715 | ||
| Secretory immunoglobulin A antibodies against the sigma1 outer capsid protein of reovirus type 1 Lang prevent infection of mouse Peyer's patches | Q36942577 | ||
| Regulatory T cells - a brief history and perspective | Q36986732 | ||
| M-cells: origin, morphology and role in mucosal immunity and microbial pathogenesis. | Q37032884 | ||
| Brain transit and ameliorative effects of intranasally delivered anti-amyloid-β oligomer antibody in 5XFAD mice | Q37042410 | ||
| Superior Efficacy of a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman Primates | Q37069793 | ||
| Nanotechnology in vaccine delivery | Q37104199 | ||
| Treg inducing adjuvants for therapeutic vaccination against chronic inflammatory diseases | Q37105550 | ||
| Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues | Q37153923 | ||
| Tc17, a unique subset of CD8 T cells that can protect against lethal influenza challenge | Q37155421 | ||
| Safety of MF59 adjuvant | Q37156975 | ||
| Pharmaceutical aspects of intranasal delivery of vaccines using particulate systems | Q37228678 | ||
| IL-10 deficiency unleashes an influenza-specific Th17 response and enhances survival against high-dose challenge | Q37297787 | ||
| Nanoparticles for nasal vaccination. | Q37361736 | ||
| Mucins, mucus, and sputum | Q37388225 | ||
| Intranasal vaccination promotes detrimental Th17-mediated immunity against influenza infection. | Q37510582 | ||
| Mucosal vaccines: recent progress in understanding the natural barriers. | Q37642613 | ||
| Norwalk virus-like particles as vaccines | Q37706587 | ||
| Function of mucosa-associated lymphoid tissue in antibody formation | Q37744898 | ||
| Liposomes as delivery systems for nasal vaccination: strategies and outcomes | Q37748791 | ||
| New insights into the development of lymphoid tissues | Q37779724 | ||
| Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns | Q37800358 | ||
| Anti-tumor immune responses induced by iNKT cell-based immunotherapy for lung cancer and head and neck cancer | Q37846981 | ||
| Live attenuated influenza vaccine (FluMist®; Fluenz™): a review of its use in the prevention of seasonal influenza in children and adults | Q37921281 | ||
| Intranasal drug delivery: an efficient and non-invasive route for systemic administration: focus on opioids. | Q37998744 | ||
| Recent progress in mucosal vaccine development: potential and limitations | Q38029250 | ||
| Clinical implications for breath-powered powder sumatriptan intranasal treatment | Q38117699 | ||
| Dendritic cells and other innate determinants of T helper cell polarisation. | Q38131249 | ||
| Innate lymphoid cells in inflammation and immunity | Q38252609 | ||
| Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues | Q38307300 | ||
| The biology of innate lymphoid cells | Q38319907 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 34-45 | |
| P577 | publication date | 2016-12-09 | |
| P1433 | published in | Human Vaccines & Immunotherapeutics | Q21072749 |
| P1476 | title | Current prospects and future challenges for nasal vaccine delivery | |
| P478 | volume | 13 |
| Q98513637 | A vaccine combination of lipid nanoparticles and a cholera toxin adjuvant derivative greatly improves lung protection against influenza virus infection |
| Q90249644 | Comparative models for human nasal infections and immunity |
| Q55097822 | Curdlan sulfate-O-linked quaternized chitosan nanoparticles: potential adjuvants to improve the immunogenicity of exogenous antigens via intranasal vaccination. |
| Q90699208 | Nasal vaccine delivery attenuates brain pathology and cognitive impairment in tauopathy model mice |
| Q64974251 | Oral Vaccine Delivery for Intestinal Immunity-Biological Basis, Barriers, Delivery System, and M Cell Targeting. |
| Q53099408 | Patient-centered drug delivery and its potential applications for unmet medical needs. |
| Q98771627 | Prospects for RNAi Therapy of COVID-19 |
| Q90080079 | Vaccine Production to Protect Animals Against Pathogenic Clostridia |
Search more.